INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality in the United States (US), causing over 500,000 cases of pneumonia, over 40,000 cases of invasive pneumococcal disease, and 4,000 associated deaths annually [1, 2] . S. pneumoniae is differentiated by one of at least 90 different polysaccharide capsules [3] . The capsule acts as the major virulence factor protecting the pathogen from destruction by host phagocytes [3] . S. pneumoniae is part of the normal bacterial flora of the upper respiratory tract and is mainly found in the nasopharynx [4] .
Pneumococcus causes a wide variety of invasive (such as bacteremia and meningitis) and non-invasive infections (such as pneumonia, sinusitis, and otitis media) [5, 6] . A number of patient demographics and comorbidities, including age, diabetes mellitus, chronic lung disease, chronic liver disease, chronic cardiovascular disease, chronic renal failure, and immune deficiencies, increase one's risk of developing pneumococcal disease [7] [8] [9] [10] [11] .
In patients with underlying medical conditions the incidence of pneumococcal infections may be as high as 176-483 per 100,000 persons, while the incidence for patients with immunocompromising conditions has been reported to be even higher from 342 to 2,031 per 100,000 persons [7, 12] .
Since the introduction and widespread use of the pneumococcal conjugate vaccine in children in 2000, the incidence of invasive pneumococcal disease in the US has decreased [13] [14] [15] [16] [17] [18] . Vaccinating children provides indirect protection or ''herd immunity'' to nonvaccinated adults, and has led to a nearly onethird decrease in the rate of invasive pneumococcal disease among adults aged 50 and older [14, 18] pneumoniae infections over the study period (Table 2) . Non-invasive pneumonia was the most common infection (63.4%, n = 9,193), followed by bacteremia (25.7%, n = 3,735), bacteremic pneumonia (10.5%, n = 1,529), bacteremia and meningitis (0.2%, n = 23), and meningitis alone (0.1%, n = 21). The overall mean age of this population was 67.7 ± 10.6 years. The majority of patients were white males from facilities in the South for all infection types. The most common treating specialty was general medicine (57.5%, n = 8,351), followed by intensive care (25.9%, n = 3,758).
Approximately 30% of patients in each infection group received the pneumococcal vaccine ( (n = 5,274) versus non-vaccination (n = 9,237) in the previous 10 years (data not presented).
DISCUSSION
We assessed the burden of invasive and noninvasive pneumococcal disease in a large population of adults aged 50 years and older receiving care at outpatient and inpatient VA facilities nationally. While outpatient incidence decreased, a small, non-significant increase in pneumococcal infections was observed in the hospital setting over our 10-year study period.
The decrease in outpatient incidence in our population is likely associated with routine pneumococcal conjugate vaccination in children. Previous studies have demonstrated decreasing rates of invasive and non-invasive pneumococcal disease, otitis media and pneumonia, including post-introduction of the pneumococcal conjugate vaccine [14, 18, [27] [28] [29] . It is possible that non-vaccine serotypes were responsible for the slight increase in pneumococcal disease we observed in our inpatient population; however, serotype data were not available. In a previous multi-center observational study the annual rate of bacteremic pneumococcal disease due to vaccine serotypes declined by 29% per year; however, the rate of disease due to non-vaccine serotypes increased by 13% per year, resulting in an overall annual increase [30] .
Our aging Veteran population may also explain the slight increase in inpatient pneumococcal infections we observed.
Incidence increased in patients aged 65 years and older, while incidence decreased in younger patients. Elderly patients are at the highest risk for pneumococcal disease and disease incidence in these patients is up to 50 times greater than that of adolescents [31] . As the general population ages, the burden of pneumococcal disease is expected to dramatically increase [32] .
This increase may be exacerbated in the Veteran population, which is older than the general population and is aging at a disproportionate rate compared to the general population [33] [34] [35] . [45] . The pneumococcal bacteremia and meningitis mortality rates we observed also agreed with previous findings, which range from 10% to greater than 40% [46] [47] [48] [49] [50] . Overall, one-third of the patients in our study with serious infections had a history of pneumococcal vaccination, which is much lower than the previously reported vaccination rate of 85% for patients at VA facilities nationally in 2003 [51] . As we conducted our study in older adults and observed significant increases in risk factors for S. pneumonia, it is likely that a number of these non-vaccinated patients had indications for vaccination. This is extremely concerning as non-vaccinated patients with indications for vaccination are more likely to become infected with pneumococcus than those without indications, and non-vaccinated patients are also twice as likely to die if they develop invasive pneumococcal disease [52, 53] .
The sickest patients in our study were more likely to receive pneumococcal vaccination. Therefore, the vaccinated patients likely had more healthcare exposures resulting in greater opportunities to receive a pneumococcal vaccination than the non-vaccinated patients. [38] . For the inpatient population, we attempted to increase the specificity of respiratory cultures by requiring a diagnosis code for pneumonia. We did not include S.
pneumoniae antigen detection tests to define pneumococcal disease. Pneumococcal urinary antigen tests may be adequate to diagnose pneumococcal pneumonia; however, sputum cultures are often still indicated at the point of care for sensitivity testing to confirm the appropriate antimicrobial treatment [38] .
Our vaccination rates may be lower than that previously reported as we defined vaccination as documentation of pneumococcal vaccination administration in the previous 1, 5, and 10 years, while the earlier study considered vaccinated patients to be those with any prior medical documentation indicating receipt of a vaccination [51] . Patients may have received a pneumococcal vaccination outside the VA which would underestimate our vaccination rates. However, our pneumococcal vaccination rates are comparable to the national vaccination rate of 20.1% for high-risk adults aged 19-64 reported in the 2011 National Health Interview Survey [54] .
Due to the retrospective nature of this study, isolates were not available and as such serotype data were not available. Data on immunosuppressant use, such as corticosteroid and chemotherapy, were not available, which are risk factors for pneumococcal disease. Additionally, there is always the potential for misclassification when relying on ICD-9 codes; however, disease coding in the VA database has been validated for a number of conditions and is determined to be of high quality [55] [56] [57] [58] ). Moreover, we identified pneumococcal infections using microbiology data rather than ICD-9 codes. Finally, the generalizability of our study is limited to the Veteran population.
CONCLUSION
We described the epidemiology of invasive and non-invasive pneumococcal disease in a large, national population of older adults, who are at the greatest risk for pneumococcal infections.
We observed a concerning trend of increasing S. 
